Current Hepatology Reports

, Volume 17, Issue 4, pp 466–474 | Cite as

New Advances in Hepatitis B Vaccination for Adults

  • Qingyao Daniel Huang
  • Seng-Gee LimEmail author
Hepatitis B (J Lim, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Hepatitis B


Purpose of Review

The mainstay of elimination of hepatitis B virus is through primary prevention by vaccination recommended by the World Health Organization. This review seeks to update readers on the performance of the current second-generation vaccine and the challenges including primary and secondary vaccine failure, as well as compliance and coverage.

Recent Findings

Primary vaccine failure in children may be overcome by HBIG and antiviral therapy in high-risk pregnancies, while in adults, a number of strategies to address this include intradermal delivery, double-dose vaccination, improved adjuvants, and a third-generation vaccine with pre-S1 and pre-S2 proteins. However, there is still no accepted standard therapy for primary vaccine failure. Secondary vaccine failure is less problematic with 3.9% of vaccines developing anti-HBc antibody, but only one reported case of chronicity has developed after vaccination.


The current second-generation prophylactic hepatitis B vaccines have performed extremely well, but there remain some challenges with regard to vaccine failure. A number of different strategies have been used to overcome this. Overall vaccine failure constitutes a relatively small proportion of vaccinees.


Hepatitis B vaccine Primary vaccine failure Secondary vaccine failure Vaccine non-compliance Pre-S1 Pre-S2 Adjuvants 


Compliance with Ethical Standards

Conflict of Interest

Seng-Gee Lim reports grants, personal fees, and non-financial support from Gilead Sciences; personal fees from Abbvie; grants and personal fees from Abbott Diagnostics; grants and personal fees from Merck; grants and personal fees from Roche; and personal fees from Springbank outside the submitted work. Qingyao Daniel Huang declares no potential conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Hepatitis B [Internet]. World Health Organization. [cited 2018 Jul 12]. Available from:
  2. 2.
    Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55.CrossRefGoogle Scholar
  3. 3.
    Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52.CrossRefGoogle Scholar
  4. 4.
    Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004;38(10 Suppl 3):S158–68.CrossRefGoogle Scholar
  5. 5.
    Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol. 2006;78(2):169–77.CrossRefGoogle Scholar
  6. 6.
    Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981;1(5):377–85.CrossRefGoogle Scholar
  7. 7.
    Stephenne J. Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness. Vaccine. 1988;6(4):299–303.CrossRefGoogle Scholar
  8. 8.
    Klimek JJ, Brettman L, Neuhaus E, Garibaldi RA. A multi-hospital hepatitis B vaccine program: prevalence of antibody and acceptance of vaccination among high-risk hospital employees. Infect Control. 1985;6(1):32–4.CrossRefGoogle Scholar
  9. 9.
    Möst J, Larcher C, Vogetseder W, Prodinger WM, Huemer HP, Ebenbichler CF, et al. Recombinant versus plasma-derived hepatitis B vaccine: comparison of immunogenicity in medical students. Vaccine. 1992;10(11):740–1.CrossRefGoogle Scholar
  10. 10.
    Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine 1990;8 Suppl:S69–73; discussion S79–80.Google Scholar
  11. 11.
    • Van Den Ende C, Marano C, Van Ahee A, Bunge EM, De Moerlooze L. The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience. Expert Rev Vaccines. 2017;16(8):811–32 A systematic review of Engerix B showing seroprotection rates of more than 90% in adults with an acceptable safety profile. CrossRefGoogle Scholar
  12. 12.
    • Schillie S. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67. Available from: The most up-to-date recommendations from the CDC regarding hepatitis B vaccination.
  13. 13.
    Halsey NA, Duclos P, Van Damme P, Margolis H. Hepatitis B vaccine and central nervous system demyelinating diseases. Viral Hepatitis Prevention Board Pediatr Infect Dis J. 1999;18(1):23–4.PubMedGoogle Scholar
  14. 14.
    Destefano F, Weintraub ES, Chen RT. Hepatitis B vaccine and risk of multiple sclerosis. Pharmacoepidemiol Drug Saf. 2007;16(6):705–7 author reply 707-708.CrossRefGoogle Scholar
  15. 15.
    WHO | Global hepatitis report 2017. WHO. [cited 2018 Jul 12]. Available from:
  16. 16.
    • Immunization coverage [Internet]. World Health Organization. [cited 2018 Jul 21]. Available from: World Health Organization data describing global coverage of newborns with the Hepatitis B vaccine.
  17. 17.
    • Auta A, Adewuyi EO, Kureh GT, Onoviran N, Adeloye D. Hepatitis B vaccination coverage among health-care workers in Africa: a systematic review and meta-analysis. Vaccine. 2018. Review showing suboptimal hepatitis B vaccine coverage among health care workers in Africa and describes reasons for poor compliance. Google Scholar
  18. 18.
    Ghendon Y. WHO strategy for the global elimination of new cases of hepatitis B. Vaccine. 1990;8(Suppl):S129–33 discussion S134–138.CrossRefGoogle Scholar
  19. 19.
    Froehlich H, West DJ. Compliance with hepatitis B virus vaccination in a high-risk population. Ethn Dis. 2001;11(3):548–53.PubMedGoogle Scholar
  20. 20.
    Panhotra BR, Saxena AK, Al-Hamrani HA, Al-Mulhim A. Compliance to hepatitis B vaccination and subsequent development of seroprotection among health care workers of a tertiary care center of Saudi Arabia. Am J Infect Control. 2005;33(3):144–50.CrossRefGoogle Scholar
  21. 21.
    Omotowo IB, Meka IA, Ijoma UN, Okoli VE, Obienu O, Nwagha T, et al. Uptake of hepatitis B vaccination and its determinants among health care workers in a tertiary health facility in Enugu, South-East, Nigeria. BMC Infect Dis [Internet]. 2018 [cited 2018 Jul 24];18. Available from:
  22. 22.
    Luman ET, McCauley MM, Stokley S, Chu SY, Pickering LK. Timeliness of childhood immunizations. Pediatrics. 2002;110(5):935–9.CrossRefGoogle Scholar
  23. 23.
    Wu J, Li D, Zhou Y. Association between timely initiation of hepatitis B vaccine and completion of the hepatitis B vaccine and national immunization program vaccine series. Int J Infect Dis. 2016;51:62–5.CrossRefGoogle Scholar
  24. 24.
    WHO | Hepatitis B vaccination timing: results from demographic health surveys in 47 countries [Internet]. [cited 2018 Jul 23]. Available from:
  25. 25.
    Wallace AS, Sobel H, Ryman TK, Mantaring JB, Silvestre M, Thorley M, et al. Timing of hepatitis B vaccination and impact of non-simultaneous vaccination with DTP vaccine following introduction of a hepatitis B birth dose in the Philippines. J Public Health Policy. 2012;33(3):368–81.CrossRefGoogle Scholar
  26. 26.
    • Whitford K, Liu B, Micallef J, Yin JK, Macartney K, Van Damme P, et al. Long-term impact of infant immunization on hepatitis B prevalence: a systematic review and meta-analysis. Bull World Health Organ. 2018;96(7):484–97 A systematic review and meta-analysis of the long-term impact of newborn vaccination on hepatitis B prevalence. This study also provides definitions for primary and secondary vaccine failure. CrossRefGoogle Scholar
  27. 27.
    Schillie SF, Murphy TV. Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review. Vaccine. 2013;31(21):2506–16.CrossRefGoogle Scholar
  28. 28.
    Lai M-W, Lin T-Y, Tsao K-C, Huang C-G, Hsiao M-J, Liang K-H, et al. Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination. Gastroenterology. 2012;143(2):400–7.CrossRefGoogle Scholar
  29. 29.
    Wu T-W, Lin HH, Wang L-Y. Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology. 2013;57(1):37–45.CrossRefGoogle Scholar
  30. 30.
    •• Tai C-S, Wu J-F, Chen H-L, Ni Y-H, Hsu H-Y, Chang M-H. The impact of hepatitis B vaccine failure on long-term natural course of chronic hepatitis B virus infection in hepatitis B e antigen-seropositive children. J Infect Dis. 2017;216(6):662–9 A large cohort study from Taiwan that reports long-term consequences of vaccine failure. CrossRefGoogle Scholar
  31. 31.
    Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2(8359):1099–102.CrossRefGoogle Scholar
  32. 32.
    Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat. 2012;19(2):e18–25.CrossRefGoogle Scholar
  33. 33.
    Lin X, Guo Y, Zhou A, Zhang Y, Cao J, Yang M, et al. Immunoprophylaxis failure against vertical transmission of hepatitis B virus in the Chinese population: a hospital-based study and a meta-analysis. Pediatr Infect Dis J. 2014;33(9):897–903.CrossRefGoogle Scholar
  34. 34.
    Zanetti AR, Tanzi E, Manzillo G, Maio G, Sbreglia C, Caporaso N, et al. Hepatitis B variant in Europe. Lancet. 1988;2(8620):1132–3.CrossRefGoogle Scholar
  35. 35.
    Jackson Y, Chappuis F, Mezger N, Kanappa K, Loutan L. High immunogenicity of delayed third dose of hepatitis B vaccine in travellers. Vaccine. 2007;25(17):3482–4.CrossRefGoogle Scholar
  36. 36.
    André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med. 1989;87(3A):14S–20S.CrossRefGoogle Scholar
  37. 37.
    Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis. 2002;35(11):1368–75.CrossRefGoogle Scholar
  38. 38.
    de Rave S, Heijtink RA, Bakker-Bendik M, Boot J, Schalm SW. Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers. Vaccine. 1994;12(6):532–4.CrossRefGoogle Scholar
  39. 39.
    Alavian S-M, Tabatabaei SV. The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: a meta-analysis of current literature. Vaccine. 2010;28(22):3773–7.CrossRefGoogle Scholar
  40. 40.
    Jiang H-Y, Wang S-Y, Deng M, Li Y-C, Ling Z-X, Shao L, et al. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine. 2017;35(20):2633–41.CrossRefGoogle Scholar
  41. 41.
    de Mattos AA, Gomes EB, Tovo CV, Alexandre COP, Remião JO d R. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. Arq Gastroenterol. 2004;41(3):180–4.CrossRefGoogle Scholar
  42. 42.
    Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine. 2005;23(22):2902–8.CrossRefGoogle Scholar
  43. 43.
    Fan W, Chen X-F, Shen C, Guo Z-R, Dong C. Hepatitis B vaccine response in obesity: a meta-analysis. Vaccine. 2016;34(40):4835–41.CrossRefGoogle Scholar
  44. 44.
    Winter AP, Follett EA, McIntyre J, Stewart J, Symington IS. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine. 1994;12(9):771–2.CrossRefGoogle Scholar
  45. 45.
    Li Z-K, Nie J-J, Li J, Zhuang H. The effect of HLA on immunological response to hepatitis B vaccine in healthy people: a meta-analysis. Vaccine. 2013;31(40):4355–61.CrossRefGoogle Scholar
  46. 46.
    Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology. 2004;39(4):978–88.CrossRefGoogle Scholar
  47. 47.
    Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis. 1999;179(2):489–92.CrossRefGoogle Scholar
  48. 48.
    Szmuness W, Stevens CE, Harley EJ, Zang EA, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med. 1982;307(24):1481–6.CrossRefGoogle Scholar
  49. 49.
    • Werner JM, Abdalla A, Gara N, Ghany MG, Rehermann B. The hepatitis B vaccine protects re-exposed healthcare workers, but does not provide sterilizing immunity. Gastroenterology. 2013;145(5). Available from: Describes how HBsAg vaccine protects against chronic infection but is not sterilizing, as evidenced by HBcore- and polymerase-specific CD8+ T cells in vaccinated personnel.):1026–34.CrossRefGoogle Scholar
  50. 50.
    Keating SM, Heitman JD, Wu S, Deng X, Stramer SL, Kuhns MC, et al. Cytokine and chemokine responses in the acute phase of hepatitis B virus replication in naive and previously vaccinated blood and plasma donors. J Infect Dis. 2014;209(6):845–54.CrossRefGoogle Scholar
  51. 51.
    • O’Halloran JA, De Gascun CF, Dunford L, Carr MJ, Connell J, Howard R, et al. Hepatitis B virus vaccine failure resulting in chronic hepatitis B infection. J Clin Virol. 2011;52(2):151–4 A case report of secondary vaccine failure in an immune competent adult resulting in the development of chronic hepatitis B. Escape mutants were not detected. CrossRefGoogle Scholar
  52. 52.
    Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med. 2004;351(27):2832–8.CrossRefGoogle Scholar
  53. 53.
    Fabrizi F, Dixit V, Magnini M, Elli A, Martin P. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther. 2006;24(3):497–506.CrossRefGoogle Scholar
  54. 54.
    Dhillon S, Moore C, Li SD, Aziz A, Kakar A, Dosanjh A, et al. Efficacy of high-dose intra-dermal hepatitis B virus vaccine in previous vaccination non-responders with chronic liver disease. Dig Dis Sci. 2012;57(1):215–20.CrossRefGoogle Scholar
  55. 55.
    Kim Y-C, Prausnitz MR. Enabling skin vaccination using new delivery technologies. Drug Deliv Transl Res. 2011;1(1):7–12.CrossRefGoogle Scholar
  56. 56.
    Betancourt AA, Delgado CAG, Estévez ZC, Martínez JC, Ríos GV, Aureoles-Roselló SRM, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis. 2007;11(5):394–401.CrossRefGoogle Scholar
  57. 57.
    Borges O, Tavares J, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci. 2007;32(4–5):278–90.CrossRefGoogle Scholar
  58. 58.
    Soares E, Jesus S, Borges O. Oral hepatitis B vaccine: chitosan or glucan based delivery systems for efficient HBsAg immunization following subcutaneous priming. Int J Pharm. 2018;535(1):261–71.CrossRefGoogle Scholar
  59. 59.
    Cardell K, Akerlind B, Sällberg M, Frydén A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis. 2008;198(3):299–304.CrossRefGoogle Scholar
  60. 60.
    Wiedmann M, Liebert UG, Oesen U, Porst H, Wiese M, Schroeder S, et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology. 2000;31(1):230–4.CrossRefGoogle Scholar
  61. 61.
    Idilman R, De MN, Colantoni A, Nadir A, Van Thiel DH. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis. C. Am J Gastroenterol. 2002;97(2):435–9.CrossRefGoogle Scholar
  62. 62.
    • Guidelines, recommendations and resources | Dialysis Safety | CDC [Internet]. 2017 [cited 2018 Aug 21]. Available from: Guidelines from the CDC recommending a higher dose of hepatitis B vaccine for patients on hemodialysis.
  63. 63.
    Ni JD, Xiong YZ, Wang XJ, Xiu LC. Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis? Int J STD AIDS. 2013;24(2):117–22.CrossRefGoogle Scholar
  64. 64.
    Chaiklang K, Wipasa J, Chaiwarith R, Praparattanapan J, Supparatpinyo K. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial. PLoS One. 2013;8(11):e80409.CrossRefGoogle Scholar
  65. 65.
    Mahboubi A, Fazeli MR, Dinarvand R, Samadi N, Sharifzadeh M, Ilka H, et al. Comparison of the adjuvanticity of aluminum salts and their combination in hepatitis B recombinant protein vaccine in assessed mice. Iran J Immunol. 2008;5(3):163–70.PubMedGoogle Scholar
  66. 66.
    Saade F, Honda-Okubo Y, Trec S, Petrovsky N. A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine. 2013;31(15):1999–2007.CrossRefGoogle Scholar
  67. 67.
    Alavian S-M, Tabatabaei S-V. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials. Clin Ther. 2010;32(1):1–10.CrossRefGoogle Scholar
  68. 68.
    •• A two-dose hepatitis B vaccine for adults (Heplisav-B). JAMA 2018;319(8):822–3. A review article describing a two-dose hepatitis B vaccine. Google Scholar
  69. 69.
    Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R, et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine. 2006;24(1):20–6.CrossRefGoogle Scholar
  70. 70.
    Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine. 2012;30(15):2556–63.CrossRefGoogle Scholar
  71. 71.
    Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age. Vaccine. 2013;31(46):5300–5.CrossRefGoogle Scholar
  72. 72.
    • Jackson S, Lentino J, Kopp J, Murray L, Ellison W, Rhee M, et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine. 2018;36(5):668–74 A large phase III randomized controlled trial comparing a novel two-dose hepatitis B vaccine against a second generation vaccine. CrossRefGoogle Scholar
  73. 73.
    •• Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep. 2018;67(15):455–8 The CDC recommendations regarding a two-dose hepatitis B vaccine. CrossRefGoogle Scholar
  74. 74.
    Yerushalmi B, Raz R, Blondheim O, Shumov E, Koren R, Dagan R. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens in neonates. Pediatr Infect Dis J. 1997;16(6):587–92.CrossRefGoogle Scholar
  75. 75.
    Raz R, Koren R, Bass D. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens in adults. Isr Med Assoc J. 2001;3(5):328–32.PubMedGoogle Scholar
  76. 76.
    Young MD, Schneider DL, Zuckerman AJ, Du W, Dickson B, Maddrey WC, et al. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine. Hepatology. 2001;34(2):372–6.CrossRefGoogle Scholar
  77. 77.
    Krawczyk A, Ludwig C, Jochum C, Fiedler M, Heinemann FM, Shouval D, et al. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. Vaccine. 2014;32(39):5077–82.CrossRefGoogle Scholar
  78. 78.
    • Elhanan E, Boaz M, Schwartz I, Schwartz D, Chernin G, Soetendorp H, et al. A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B®, among vaccine naïve and vaccine non-responder dialysis patients. Clin Exp Nephrol. 2018;22(1):151–8 A randomized controlled trial comparing immunogenicity in the third-generation vaccine against the second generation vaccine in dialysis patients. CrossRefGoogle Scholar
  79. 79.
    Etzion O, Novack V, Perl Y, Abel O, Schwartz D, Munteanu D, et al. Sci-B-VacTM vs ENGERIX-B vaccines for hepatitis B virus in patients with inflammatory bowel diseases: a randomised controlled trial. J Crohns Colitis. 2016;10(8):905–12.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Gastroenterology and Hepatology, Dept of MedicineNational University Health SystemSingaporeSingapore
  2. 2.Faculty of Medicine, Yong Loo Lin School of MedicineNational University of SingaporeSingaporeSingapore
  3. 3.Department of Gastroenterology and HepatologyNational University HospitalSingaporeSingapore

Personalised recommendations